AI in Pharmacovigilance: Case Processing at Scale Under Good Pharmacovigilance Practice

Pharmacovigilance case processing is one of the most labour-intensive, regulation-heavy, and consequential workflows in the life sciences industry. Every Individual Case Safety Report (ICSR) that arrives at a pharmaceutical company, whether from a healthcare professional, a patient, a clinical trial, or a literature source, must be triaged, assessed, coded, narrated, and submitted to the relevant regulatory authority within strict timelines. Serious cases have 15-day reporting windows. The volume is relentless: a large pharmaceutical company processes tens of thousands of ICSRs per year across its portfolio.

The structural problem is that case processing has scaled linearly with volume. Twice the cases means approximately twice the case officers. This is unsustainable for two reasons: the cost is growing faster than revenue in many therapeutic areas, and the talent pool of qualified case officers is shrinking as demand outstrips the pipeline of trained pharmacovigilance professionals.

AI enablement in pharmacovigilance is not about replacing case officers. It is about redesigning the case processing workflow so that AI handles the structured, repeatable components of case processing (intake triage, MedDRA coding, narrative first-draft generation, duplicate detection, literature screening) while case officers concentrate on the genuinely ambiguous cases: the serious unexpected adverse reactions, the signals that might indicate a new safety concern, the cases where clinical judgment determines whether a product's benefit-risk profile has changed.

This post covers what that redesign looks like in practice, under the regulatory expectations set by the European Medicines Agency (EMA), the US FDA, the ICH guidelines (particularly ICH E2B(R3) for electronic transmission and ICH E2E for pharmacovigilance planning), and the WHO Uppsala Monitoring Centre for global signal detection.

The regulatory framework: GVP as the operating constraint

Good Pharmacovigilance Practice (GVP) is the regulatory framework that governs how pharmaceutical companies collect, assess, and report adverse drug reactions. In the EU, GVP is defined by the EMA across a series of modules. In the US, the FDA's post-marketing safety reporting requirements under 21 CFR 314.80 and 314.98 serve a similar function. In the UK, the MHRA applies its own pharmacovigilance guidance aligned with but not identical to the EU framework.

The critical constraint for AI in pharmacovigilance is that GVP does not prescribe how case processing must be done, but it prescribes the outcomes that must be achieved: timely reporting, accurate coding, complete narratives, defensible causality assessments, and audit trails that demonstrate compliance. Any AI system that participates in case processing must produce outcomes that satisfy these requirements, and the pharmaceutical company remains fully accountable for every case regardless of whether a human or a system performed any given step.

This accountability structure means that AI in pharmacovigilance is always AI-assisted, never AI-autonomous. The case officer reviews, verifies, and accepts or overrides every AI output. The AI system's value is not in removing the human from the loop; it is in doing the structured preparation work so that the human's time is spent on judgment rather than data entry.

GxP validation requirements

Any software system used in a GxP-regulated process must be validated to demonstrate that it performs as intended, consistently and reproducibly. For AI systems, this creates a specific challenge: the model's behaviour may change with retraining, and the validation must cover not just the current model version but the change control process for model updates.

The practical implication: the AI system must have a documented validation protocol, a change control procedure that requires revalidation when the model is updated, and an audit trail that records every model version, every prediction, and every human decision. This is not optional. It is a regulatory requirement under GxP, and failure to comply can result in regulatory action up to and including marketing authorisation withdrawal.

Where AI delivers value in the case processing workflow

The ICSR processing workflow has several stages where AI can deliver substantial value without requiring autonomous decision-making:

1. Intake triage and duplicate detection

Every incoming report (from MedWatch, EudraVigilance, spontaneous reports, clinical trial data, literature, social media monitoring) must be triaged: is this a valid ICSR? Is it a duplicate of a case already in the database? What is the initial seriousness and expectedness assessment?

AI-based triage models can classify incoming reports with high accuracy, flag probable duplicates for human verification, and perform initial seriousness coding. The case officer reviews the triage output rather than performing it from scratch. For a high-volume PV operation, this step alone can reduce intake processing time by 40-60%.

The data flywheel starts here: every time a case officer accepts or corrects the AI's triage classification, that decision becomes training signal for the next model iteration. Over time, the triage model learns the specific patterns of each product's adverse event profile.

2. MedDRA coding

The Medical Dictionary for Regulatory Activities (MedDRA) is the controlled terminology used to code adverse events, indications, and medical history in ICSRs. Accurate MedDRA coding is essential for signal detection and regulatory submission. It is also one of the most time-consuming steps in case processing, particularly for complex cases with multiple adverse events described in non-standard language.

AI-based MedDRA coding tools (using NLP to extract adverse events from source text and map them to MedDRA Preferred Terms and Lowest Level Terms) have reached the point where they match experienced case officers on straightforward cases and provide useful first-pass coding on complex cases that the case officer then refines.

The governance requirement: every AI-suggested code must be reviewed and accepted or modified by a qualified case officer. The system must log both the AI suggestion and the final human decision, creating the structured feedback that powers the flywheel.

3. Narrative drafting

Every ICSR includes a case narrative: a structured summary of the patient, the adverse event, the suspect product, the timeline, the outcome, and the reporter's assessment. Writing narratives is repetitive for straightforward cases and time-consuming for complex ones.

Large language models can generate high-quality first-draft narratives from structured case data. The case officer reviews, edits, and approves the narrative rather than writing it from scratch. For routine cases, the review is fast because the narrative follows a standard template. For complex cases, the AI-generated first draft provides a starting point that the case officer refines with clinical judgment.

The validation challenge is ensuring that the generated narrative is factually accurate (no hallucinated details, no omitted information) and that the case officer has an efficient workflow for verifying accuracy. This is a workflow design challenge, not just a technology challenge.

4. Signal detection and literature screening

Signal detection is the process of identifying new, previously unrecognised adverse reactions or changes in the frequency or severity of known reactions. It involves statistical analysis of case databases (disproportionality analysis), literature review, and clinical assessment. The WHO Uppsala Monitoring Centre operates VigiBase, the global ICSR database, and provides signal detection tools and methodology.

AI enhances signal detection in two ways: it can run disproportionality analysis continuously rather than periodically, and it can screen the published literature and social media for safety-relevant information far more comprehensively than a human team can. The output is a prioritised list of potential signals for the safety scientist to evaluate, not an autonomous signal determination.

Literature screening, in particular, has become a high-volume task as the number of published sources, conference abstracts, and online forums that must be monitored has grown. AI-based literature screening tools can process thousands of articles per day and surface the ones that contain safety-relevant information for human review.

The operating model shift

AI enablement in pharmacovigilance changes the operating model in three structural ways:

From case processors to case assessors

The case officer's role shifts from performing every step in the case processing workflow (data entry, coding, narrative writing, timeline construction) to assessing the outputs produced by the AI system and applying clinical judgment where it matters. This is a more demanding role, not a less demanding one. The case assessor needs stronger clinical knowledge, better pattern recognition skills, and the authority to override the AI system when the output is wrong.

This is the same talent shift that applies across every AI-enabled operating model: the humans in the loop do less routine work and more judgment work. The training and development programmes must evolve to support this shift.

From periodic to continuous processing

The batch model (cases arrive, are queued, and processed in daily or weekly batches) gives way to continuous processing where the AI system triages, codes, and drafts narratives in near-real-time as cases arrive. Case officers work through a prioritised queue where the most urgent and most complex cases surface first, and routine cases arrive pre-processed and ready for rapid review.

This continuous processing model compresses cycle times and reduces the risk of missing regulatory reporting deadlines. It also produces a more even workload distribution, reducing the peak-load staffing problem that many PV operations face.

From compliance evidence as a project to compliance evidence as a by-product

Under the current model, preparing for a regulatory inspection or an internal audit means assembling evidence from multiple systems: case processing logs, training records, SOP compliance documentation, signal detection reports. This assembly process is manual, time-consuming, and error-prone.

In the AI-enabled model, compliance evidence is produced as a by-product of the workflow. Every AI prediction, every human decision, every override, every model version, every validation result is logged in the action-data layer in structured form. When the inspector arrives, the evidence is queryable on demand rather than assembled from disparate sources. This is the embedded governance approach applied to life sciences.

Building the data flywheel in PV

The data flywheel in pharmacovigilance has a specific and powerful form. Every case officer decision, whether accepting an AI-suggested MedDRA code, modifying a generated narrative, overriding a triage classification, or confirming a duplicate detection, is a labelled training example that makes the next model iteration more accurate.

The flywheel spins faster in PV than in many other domains because:

1. Labels come back immediately. The case officer's accept/modify/override decision is the label, and it is recorded at the time of processing.
2. Volume is high. Large pharmaceutical companies process thousands of cases per month.
3. The feedback is structured. MedDRA codes, seriousness assessments, and causality assessments are all coded in controlled vocabularies, which makes the training signal clean.

The governance requirement for the flywheel is a validated retraining pipeline that satisfies GxP change control requirements. Each model retrain must be documented, validated, and approved before deployment. The AI Governance and Model Risk course covers the model lifecycle management framework that applies here.

How to start

The first step is a diagnostic assessment of your current PV case processing workflow against the AI-native target state. Our AI Enablement for Life Sciences service includes a PV-specific diagnostic that evaluates intake, coding, narrative, signal detection, and regulatory submission workflows and identifies the highest-leverage AI enablement opportunities.

The diagnostic produces a current-state workflow map, an AI enablement opportunity assessment, a GxP validation requirements summary, and a phased implementation roadmap. The typical first phase focuses on intake triage and MedDRA coding, which deliver the fastest return and the lowest regulatory risk.

For pricing and engagement structure, see the pricing page. For the cross-sector perspective on how the data flywheel and operating model shift work in practice, the data flywheel essay and the talent shift essay provide the conceptual foundation.

The pharmaceutical industry's PV burden is growing, and the talent pool to meet it is not. AI enablement is not a future ambition; it is a present operational necessity. The companies that build the flywheel now will have structurally lower case processing costs and structurally better safety data than those that continue to scale linearly. And the regulator, whether EMA, FDA, or MHRA, will increasingly expect to see that the investment has been made.